Nanocarriers for target specific drug delivery to manage theileriosis, comprising of at least one anti-theileirial drug and one or more lipid, wherein the nanocarriers have an average size of less than 800nm, and exhibit greater than 75% uptake collectively in the liver, spleen, lungs, bone marrow and lymph nodes of the reticuloendothelial system.The anti-theileirial drug is selected from among buparvaquone and parvaquone.
